2023 MOMENTUM

GRANT> AVENUE

Grant Avenue Capital begins 2023 with excellent momentum as we build upon our accomplishments in 2022.

In recent months, we added a new platform investment, continued to drive significant growth across our portfolio, and deepened our bench with the addition of new executives. We remain focused on leading middle-market healthcare buyout investments in partnership with founders and innovative management teams to drive exceptional results.



New Platform Investment



Grant Avenue established Helios Clinical Research, a new integrated clinical site organization that partners with patients, physicians, and biopharma sponsors to optimize clinical research. Helios marks our fourth platform investment.



Recent Portfolio Highlights




H2 Health completed nine acquisitions, launched eighteen de novos, and added Applied Behavioral Analysis to three locations.



Fortis Home Health and Hospice hired key leadership, launched hospice services in Midwest region, and formed ACO partnerships.



QHR Health completed first add-on acquisition, expanded key leadership, and significantly grew its market share across multiple business lines.



~38%

Revenue Growth Acquisitions De Novos

Target Platform Size / Sectors

EBITDA: \$5 to \$25 million

Equity Check: \$25 to \$75 million

Enterprise Value: \$25 to \$350 million

Healthcare Services, Pharma Services, MedTech, HCIT



Expanding Team and Advisory Board

Continued to expand the Investment Team while also further building out the Advisory Board with additional expertise.



Brian Berkin Managing Director



Stew Jamieson Director. Business Development



Avishee Gupta Senior Associate



Eileen Wang Associate



Teresa Sparks Advisory Board



Aubrey Maze Advisory Board

Grant Avenue Capital is a healthcare focused private equity firm investing alongside forward-thinking management teams. Visit our website to download our tearsheet.